RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness - PubMed
4 hours ago
- #Real-world effectiveness
- #Pediatric prophylaxis
- #Respiratory syncytial virus
- RSV is a major cause of lower respiratory infections and hospitalizations in infants and children.
- Recent advances include long-acting monoclonal antibodies like nirsevimab and maternal RSVpreF vaccination.
- Meta-analysis of 43 studies shows about 80% effectiveness against RSV hospitalization for both nirsevimab and maternal vaccination.
- Focus is on optimizing implementation and ensuring equitable access to these prophylactics.